We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+34.57%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$712M
AUM Growth
+$90.4M
Cap. Flow
+$220K
Cap. Flow %
0.03%
Top 10 Hldgs %
33.84%
Holding
126
New
27
Increased
25
Reduced
33
Closed
22

Top Buys

Rank Stock Value
1
CATX icon
Perspective Therapeutics
CATX
+$10.6M
2
BBIO icon
BridgeBio Pharma
BBIO
+$10.3M
3
HELP
Cybin Inc
HELP
+$9.73M
4
S icon
SentinelOne
S
+$8.81M
5
JSPR icon
Jasper Therapeutics
JSPR
+$7.71M

Top Sells

Rank Stock Value
1
NVMI
Nova
NVMI
+$15.3M
2
ATXS
Astria Therapeutics
ATXS
+$12.9M
3
TSEM icon
Tower Semiconductor
TSEM
+$10.9M
4
INBX
Inhibrx, Inc. Common Stock
INBX
+$8.61M
5
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$7.61M

Sector Composition

Rank Sector Weight
1 Healthcare 65.19%
2 Technology 15.63%
3 Communication Services 2.68%
4 Consumer Discretionary 2.45%
5 Utilities 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FROG icon
26
JFrog
FROG
$9.66B
$9.92M 1.39%
224,381
+114,476
+104% +$4.43M
AMZN icon
27
Amazon
AMZN
$2.92T
$9.82M 1.38%
54,432
-1,244
-2% -$208K
FUSN
28
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$9.57M 1.35%
449,041
-636,598
-59% -$7.61M
PHVS icon
29
Pharvaris
PHVS
$2.28B
$9.08M 1.28%
392,877
+147,877
+60% +$3.93M
MLYS icon
30
Mineralys Therapeutics
MLYS
$2.25B
$8.51M 1.2%
658,803
-84,788
-11% -$1.05M
DAWN
31
DELISTED
Day One Biopharmaceuticals
DAWN
$8.14M 1.14%
492,627
-20,373
-4% -$305K
GLBE icon
32
Global E Online
GLBE
$6.6B
$7.59M 1.07%
208,784
-61,010
-23% -$2.26M
WIX icon
33
WIX.com
WIX
$2.3B
$7.27M 1.02%
52,877
-4,600
-8% -$605K
SRPT icon
34
Sarepta Therapeutics
SRPT
$1.57B
$7.2M 1.01%
55,614
+43,114
+345% +$5.28M
IMTX icon
35
Immatics
IMTX
$1.18B
$7M 0.98%
666,111
+45,000
+7% +$525K
ABBV icon
36
AbbVie
ABBV
$443B
$6.92M 0.97%
38,000
-8,000
-17% -$1.38M
OTLK icon
37
Outlook Therapeutics
OTLK
$183M
$6.82M 0.96%
+571,429
New +$4.62M
MRUS
38
DELISTED
Merus
MRUS
$6.72M 0.94%
149,333
-81,000
-35% -$3.28M
AMAT icon
39
Applied Materials
AMAT
$403B
$6.6M 0.93%
+32,000
New +$5.87M
CAMT icon
40
Camtek
CAMT
$6.18B
$6.28M 0.88%
+74,909
New +$5.89M
NVMI
41
Nova
NVMI
$12.4B
$6.23M 0.87%
35,106
-96,894
-73% -$15.3M
TSEM icon
42
Tower Semiconductor
TSEM
$24.8B
$6.01M 0.84%
179,600
-348,700
-66% -$10.9M
ETNB
43
DELISTED
89bio
ETNB
$6M 0.84%
515,882
+107,208
+26% +$1.19M
VIGL
44
DELISTED
Vigil Neuroscience
VIGL
$5.9M 0.83%
1,730,414
+1,195,294
+223% +$3.73M
ENPH icon
45
Enphase Energy
ENPH
$4.96B
$5.71M 0.8%
47,183
+12,383
+36% +$1.44M
VTYX
46
DELISTED
Ventyx Biosciences
VTYX
$5.46M 0.77%
992,749
+812,749
+452% +$3.72M
TBLA icon
47
Taboola.com
TBLA
$1.37B
$5.29M 0.74%
1,191,070
-533,878
-31% -$2.38M
FDMT icon
48
4D Molecular Therapeutics
FDMT
$532M
$5.17M 0.73%
+162,161
New +$4.14M
INCY icon
49
Incyte
INCY
$24.2B
$5.1M 0.72%
89,556
– –
RCKT icon
50
Rocket Pharmaceuticals
RCKT
$340M
$4.95M 0.7%
183,722
-7,061
-4% -$201K
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2024 Portfolio in Review

As of Q1 2024, Sphera Funds Management held 126 positions worth $712M, up 15% from $621M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Sphera Funds Management's Q1 2024 filing shows 27 new, 25 increased, 33 reduced and 22 closed positions. Its largest new stake was Cybin Inc: 673,195 shares worth $10.6M. The largest sale was Nova, an estimated $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 63% a quarter earlier, followed by Technology and Communication Services.

  • Sphera Funds Management's largest Q1 2024 buy was Cybin Inc: 673,195 shares worth $10.6M.
  • Sphera Funds Management added most to Perspective Therapeutics in Q1 2024, an estimated $10.6M increase.
  • Sphera Funds Management's biggest Q1 2024 reduction was Nova, cutting an estimated $15.3M.
  • Sphera Funds Management fully exited Inhibrx, Inc. Common Stock in Q1 2024, selling an estimated $8.61M.
  • Sphera Funds Management's ten largest holdings make up 34% of its $712M portfolio in Q1 2024.
  • Sphera Funds Management opened 27 new positions and closed 22 in Q1 2024.
  • Sphera Funds Management's portfolio value rose 15% quarter-over-quarter to $712M.

Based on Sphera Funds Management's 13F filing for Q1 2024, filed 15 May 2024.